Categories: Clinical TrialNews

Essex Management Appoints David Loose as Chief Executive Officer

Appointment Reflects Commitment to Continuing Essex’s Strategic Vision

ROCKVILLE, Md., Jan. 7, 2025 /PRNewswire/ — Essex Management, an Emmes Group company and a leader in biomedical informatics and health information technology, is pleased to announce the appointment of David Loose as Chief Executive Officer (CEO), effective immediately. David succeeds Kevin Hurley, who has served as CEO since February 2019 and will transition to the role of Executive Advisor.

David Loose joined Essex Management as a partner in February 2009 and has played a pivotal role in the company’s growth. Starting as Vice President for Business Operations and Development, he later served as Chief Business Officer, overseeing critical operations, driving client-focused innovation, and delivering strategic initiatives such as NCI’s Clinical Trials Reporting Program (CTRP). His leadership and dedication to Essex’s mission have been instrumental in building its reputation as a trusted partner in the biomedical and health technology sectors.

“David’s leadership and dedication to Essex’s mission make him the ideal choice to guide the company forward,” said Sastry Chilukuri, CEO of Emmes Group. “His focus on innovation and client success will ensure Essex continues to deliver transformative solutions in biomedical informatics and health IT.”

Essex also recognizes Kevin Hurley’s significant contributions since joining the company in 2009. As a founding partner and later as CEO, Kevin guided Essex through transformative milestones, including its acquisition by Emmes Group in 2023. “We are deeply grateful for Kevin’s leadership and dedication over the years,” said David Loose. “His vision has been instrumental in Essex‘ success, and we’re fortunate to have his continued guidance as an Executive Advisor.”

Founded in 2009 and headquartered in Rockville, Maryland, Essex Management brings together multidisciplinary teams of engineers, business analysts, and project managers with computational biologists and clinical experts. Together, they deliver innovative health and biomedical information solutions for federal agencies, research institutions, and private-sector clients.

Under David Loose’s leadership, Essex Management is poised to build on its legacy of navigating the complexities of scientific computing to save lives and improve the quality of care.

About Emmes Group:
Emmes Group, a specialty, technology and AI enabled contract research organization (CRO), is advancing and modernizing clinical research to improve patient outcomes. Founded as Emmes more than 47 years ago, we became a trusted clinical research partner to the U.S. government. Today, Emmes Group is a global full-service CRO operating in 72 countries worldwide collaborating with government agencies, public-private partnerships, and biopharma innovators. Now wholly owned by New Mountain Capital, we are transforming the future of clinical research and bringing life-changing treatments closer to patients. Where human intelligence meets artificial intelligence. Learn more at www.theemmesgroup.com.

About Essex Management:
Essex Management, an Emmes Group company, is a biomedical informatics and health information technology firm that provides tailored consulting services and advanced technology solutions. Since 2009, Essex has strategically developed and managed complex health and biomedical information programs for the Federal Government, research academia, and private sectors. Headquartered in Rockville, MD, Essex Management is committed to saving lives and improving the quality of care through innovative solutions. Learn more at www.essexmanagement.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/essex-management-appoints-david-loose-as-chief-executive-officer-302343758.html

SOURCE Emmes Group

Staff

Recent Posts

Restart Life Receives Aggregate Gross Proceeds of Approximately $590,000 from Warrant Exercises and Loan

Vancouver, British Columbia--(Newsfile Corp. - December 22, 2025) - Restart Life Sciences Corp. (CSE: HEAL)…

3 hours ago

FlyteHealth to Expand Direct Access to Obesity Management Medication for Employers

NEW CANAAN, Conn., Dec. 22, 2025 /PRNewswire/ -- FlyteHealth, a national leader in integrated cardio-kidney-metabolic care,…

3 hours ago

10 Days, 10 Ways to Spend FSA (Flexible Spending Account) Funds Before the December 31 Use-It-or-Lose-It Deadline, from FSA Store®

The clock is ticking on 2025 FSA funds, and as the use-it-or-lose-it deadline approaches, FSA…

3 hours ago

TraceLink Wins 2025 Merit Award — Recognized for Healthcare Innovation for the Third Consecutive Year

TraceLink has been named a winner of the 2025 Merit Awards for Healthcare Innovation, marking…

3 hours ago

NUCALM CELEBRATES RECORD-BREAKING DECEMBER WITH OVER 2 BILLION MINUTES USED AND LARGEST LIVE EVENT ACTIVATION EVER

Tony Robbins' "Date with Destiny" Event Drives Unprecedented Engagement with NuCalm TechnologyPALM BEACH, Fla., Dec.…

3 hours ago

Point-of-Care Is Just the Beginning: Doceree 360 Report Maps Three Strategic Imperatives for HCP Engagement Across All Digital Touchpoints

New Annual Report Reveals Opportunity for Pharma Marketers to Reach Physicians Throughout Entire Decision-Making Journey—From Learning…

3 hours ago